Are Statins Safe? The Myths, the Evidence, and the Answers

There are medicines that doctors prescribe and medicines that patients accept without question. Statins are emphatically not in the second category.

Since the first large-scale trial in the 1990s, statins have accumulated more safety data than almost any other drug class in history — over 170,000 participants across major randomised controlled trials alone. The Cholesterol Treatment Trialists (CTT) Collaboration pooled data from 27 trials and found that for every 1 mmol/L reduction in LDL, the risk of major cardiovascular events falls by 22%. That is not a modest effect. That is the kind of number that makes cardiologists feel quietly grateful for chemistry.

In Singapore, where ischaemic heart disease remains the second leading cause of death, statins are prescribed for those at elevated cardiovascular risk according to established MOH clinical guidelines. The question of whether they are safe is, at this point, answered. The more interesting question is: safe compared to what?

Somewhere along the line, “one patient reported brain fog” became “statins cause dementia.” It is an impressive piece of narrative drift.

In 2012, the US FDA added a label warning about possible cognitive effects, based on individual case reports. This is a perfectly reasonable precautionary step. It is not the same as evidence of causation — and the subsequent large-scale data has gone firmly in the opposite direction.

A 2025 meta-analysis published in Alzheimer's & Dementia: Translational Research & Clinical Interventions (Westphal Filho et al.) pooled 55 studies covering more than 7 million patients. Statin use was associated with a 14% reduction in all-cause dementia (hazard ratio 0.86) and an 18% reduction in Alzheimer's disease (HR 0.82). Vascular dementia also showed reduced incidence. If statins were quietly causing cognitive decline in Singapore patients and millions of others, a dataset of this scale would not be able to hide it.

The cancer concern has circulated for decades, and there is a plausible-sounding rationale: cholesterol is involved in cell membrane synthesis, so aggressive lowering might theoretically interfere with cell turnover. It sounds credible at a dinner party. It dissolves under actual data.

A 2023 umbrella meta-analysis on statin use and cancer risk found no increase in overall cancer incidence among statin users. More striking: statins were associated with reduced risk of several cancers — colorectal cancer down 9%, gastric cancer down 29%, liver cancer down 42%, and biliary tract cancer down 33%. The likely mechanism involves statins' anti-inflammatory and pro-apoptotic properties.

In Singapore, where colorectal and liver cancers are among the most common malignancies, this data adds an interesting dimension to the risk-benefit conversation — though statin therapy is prescribed for cardiovascular indications, not cancer prevention.

Muscle aches are the one statin side effect that genuinely deserves a conversation. Between 5% and 25% of patients report muscle discomfort, depending on whether you look at clinical trials or observational cohorts. There is, however, a crucial detail that rarely makes it into forum posts: in placebo-controlled trials, the rate of myalgia in the placebo group is nearly identical — around 5%.

This is not a conspiracy. It reflects the nocebo effect — when patients expect a side effect, they are measurably more likely to experience it. In our clinic at Paragon Medical Centre, we regularly see patients who had been labelled statin-intolerant, and who — with a different statin at a lower dose — tolerate their medication without any issue.

Genuine rhabdomyolysis — severe muscle breakdown with kidney injury — is rare. The incidence is approximately 1 in 20,000 patients at standard doses. The simvastatin 80 mg dose, which carries a higher risk (0.53%), is now rarely used in Singapore or elsewhere.

This is the question we hear most from patients who have been frightened by something they read online and are tempted to simply stop. Stopping statins is not a cliff edge — but it is not inconsequential either.

LDL cholesterol rises by approximately 45% within 2 to 3 months of stopping, and by up to 55% at 4 to 6 months. More concerning is the inflammatory rebound: CRP and IL-6 — markers linked to atherosclerotic plaque instability — spike sharply after statin withdrawal. Research published in Arteriosclerosis, Thrombosis, and Vascular Biology (Stasinopoulou et al., 2019) demonstrated that plaque destabilisation can occur independently of cholesterol changes, driven by acute inflammatory release within plaques.

For Singapore patients who have already had a heart attack or stroke, stopping statins without medical guidance carries meaningful risk. An early analysis found that abrupt withdrawal was associated with a tripling of mortality risk in high-risk patients in the months that followed. Think of it as switching off a smoke alarm rather than investigating the fire.

Being honest means acknowledging that statins are not entirely side-effect-free. They are merely far better-tolerated than the internet suggests.

Liver enzyme elevation occurs in about 1–3% of patients and is usually mild and reversible. Severe hepatotoxicity is exceedingly rare. Current ESC/EAS dyslipidaemia guidelines do not recommend routine annual liver function tests in asymptomatic patients on standard doses — one baseline test is generally sufficient.

New-onset diabetes is a modest but real risk. Statins increase the risk of diabetes by approximately 10–20% in those who are already borderline — translating to roughly 1 additional case per 255 patients treated for 4 years. For most patients at elevated cardiovascular risk in Singapore, the heart attack and stroke prevention benefit outweighs this metabolic trade-off.

Most patients on statins are managed comfortably by their GP with periodic monitoring. However, a cardiology consultation adds genuine value in specific situations — particularly if you have been labelled “statin intolerant” after stopping due to side effects, or if you are uncertain whether you need a statin in the first place.

At our clinic in Paragon Medical Centre, Orchard Road, Singapore, we see patients who were told they could not tolerate statins, and who — on structured rechallenge with a different agent at a lower dose — tolerate their medication without difficulty. The majority of patients who fail one statin can tolerate another. For the genuinely intolerant minority at high cardiovascular risk, PCSK9 inhibitors offer a non-statin alternative that is highly effective.

If you stopped a statin because of something you read online, or if you have been on one for years and have concerns, a specialist assessment can give you clear answers based on your actual risk profile — not a generalised online forum.